Heart failure is a common and growing problem, worldwide, often leading to repeated hospitalisations, reduced quality of life, disability, loss of independence and shortened life expectancy. Managing heart failure is costly and complex for individual patients, their families and healthcare systems. A range of pharmacological agents, devices and disease management programmes have proven to be effective but are not available to all patients. Non-invasive telemonitoring and structured telephone support for patients with heart failure have been researched for almost two decades; however the jury still appears to be out for the use of this intervention in clinical practice. The effectiveness of structured telephone support and non-invasive telemonitoring to reduce hospitalisations and mortality in patients with heart failure was assessed by a recent Cochrane review.
Heart failure is a common and growing problem, worldwide, often leading to repeated hospitalisations, reduced quality of life, disability, loss of independence and shortened life expectancy. Managing heart failure is costly and complex for individual patients, their families and healthcare systems. A range of pharmacological agents, devices and disease management programmes have proven to be effective but are not available to all patients. Non-invasive telemonitoring and structured telephone support for patients with heart failure have been researched for almost two decades; however the jury still appears to be out for the use of this intervention in clinical practice. 1 The effectiveness of structured telephone support and non-invasive telemonitoring to reduce hospitalisations and mortality in patients with heart failure was assessed by a recent Cochrane review. 2 This review was undertaken as an update to a previously published version. Randomised controlled trials (RCTs) that compared structured telephone support or non-invasive telemonitoring to standard practice were included. Studies were excluded if the telemonitoring intervention included other interventions such as home visits or frequent clinic visits or implanted monitoring devices. Compared with the previously published Cochrane review, 17 new studies were identified and 24 had been included in the previous review (total of 41 studies). Two studies were multiarm and included both structured telephone support and telemonitoring; hence there were 43 comparisons in the review. The primary outcomes included all-cause mortality and all-cause and heart failure related hospitalisations which were analysed using fixed-effects models.
The review demonstrated that both noninvasive telemonitoring and structured telephone support offer statistically and clinically meaningful benefits to people with heart failure. figure 2 ) and a 15% reduction in heart failure related hospitalisations (RR 0.85, 95% CI 0.77 to 0.93; participants=7030; studies=16; I 2 =27%; GRADE: moderate-quality evidence). No benefit was derived from either of these interventions on all-cause hospitalisations but the quality of this evidence was rated very low.
Secondary outcomes examined in this review included length of stay, healthrelated quality of life, cost of the intervention and cost-effectiveness, adherence to the intervention, self-care, heart failure knowledge and patient acceptance and satisfaction with the intervention, although these outcomes were reported inconsistently by the included studies. 2 Of note, most studies which examined health-related quality of life with either intervention reported significant improvements in the global measure (overall health-related quality of life) or component scores. Significant benefits were observed on heart failure knowledge and self-care behaviours for most of the small number of studies that reported these outcomes.
Five subgroup analyses were performed to examine heterogeneity among studies for the primary outcomes; none were found although this may reflect an insufficient amount of data for some analyses. The five subgroups were type of technology; telemonitoring intensity; publication year; mean/median age of study participants; and focus of structured telephone support studies. 3 4 A metaregression was performed for each subgroup to investigate whether there was enough evidence that the treatment effect differed between subgroups. The five technology types identified included: (A) telephone calls; (B) videophone; (C) interactive voice response; (D) complex/clinical telemonitoring. 3 Of note, voice interactive systems and videoconferencing appeared ineffective although statistical heterogeneity could not be confirmed. Telemonitoring studies were categorised into two groups (A) office hours (typically Monday-Friday 9:00-17:00) and (B) 24 hours/day, 7 days/week. This categorisation was based on that proposed by Anker et al. 5 Office-hours monitoring tended to have a greater effect, although tests for heterogeneity were nonsignificant. Included studies were categorised according to year of publication of the full-text, peer reviewed publication of each study according to nominal time periods for which changes in heart failure care occurred: (A) pre-2000; (B) 2000-2007; (C) since 2008. The effects appeared smaller in more recent studies, perhaps reflecting improved care in the control groups. The mean/median age of study participants was used to categorise studies into two age groups: (A) <70 years of age; (B) ≥70 years of age. 4 Age was not an important determinant of benefit. Structured telephone support studies were categorised according to the focus of the intervention: (A) clinical monitoring of heart failure signs and symptoms with clinical support provided (clinical support); (B) self-management education; effects were similar in each subgroup.
LIMITATIONS OF THIS ANALYSIS
The review was limited mostly by the amount and nature of the data available. We would have preferred to examine outcomes according to age as a continuous variable, New York Heart Association Class and sex, but these data were not available in a manner enabling such subgroup analysis. We could not report 'patient-years' as the denominator for our meta-analysis in order to adjust for varying length of follow-up as these data were unavailable.
We limited our Cochrane review to fully published, peer-reviewed studies, excluding those reported only as conference abstracts, theses or unpublished data. Hence, the results of ongoing studies identified in the searches which have since been published in full, such as the Better Effectiveness After Transition-Heart Failure trial 6 published in March 2016, could not be included. This study randomised 1437 patients to non-invasive telemonitoring or usual care and found that telemonitoring did not reduce 180-day readmission or mortality. We cannot exclude the possibility that inclusion of new studies might influence the results of the meta-analysis in future updates of this review. Thirty-four ongoing studies were identified in this review and these studies will continue to clarify the use of remote monitoring interventions such as non-invasive telemonitoring and structured telephone support for people with heart failure.
CLINICAL IMPACT
This Cochrane review underlines the clinical value of remote monitoring for people with heart failure, with significant benefits demonstrated on mortality, heart failure hospitalisation and quality of life, while also demonstrating positive impact on heart failure knowledge and self-care.
Although there may be barriers to the use of structured telephone support and telemonitoring for people with heart failure, there is considerable evidence that such approaches to care do benefit patients.
For the vast majority of people globally with heart failure without access to 'gold standard', face-to-face, heart failure management programmes the peer-reviewed, randomised controlled trial evidence summarised in this Cochrane review supports the use of structured telephone support and/or telemonitoring as an alternative for such patients. Disappointingly, the recently released European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure 1 did not recommend telemonitoring or structured telephone support, despite the findings of this Cochrane review. In fact, our Cochrane review was not mentioned in the European Society of Cardiology (ESC) Guidelines and the only evidence referenced was five selected randomised controlled trials and a narrative review on the topic published in 2011. 5 These guidelines also highlighted the use of remote monitoring in heart failure as a gap in the research and recommend further research. However, Cochrane Reviews, such the one we conducted, are widely accepted as one of the methodologically most rigorous approaches to evaluating the effects of interventions.
CONCLUSIONS
There is considerable evidence that structured telephone support or non-invasive telemonitoring improves the management, well-being and outcome of patients with heart failure. However, benefit may be highly dependent on the quality of care in the control as well as intervention groups. Remote monitoring is likely to be most effective when introduced into a healthcare environment where the quality of care for heart failure or access to specialised care is poor. Monitoring may make little or no difference when the quality of care is already high and there is good access to such care. The value of noninvasive monitoring for the early detection and management of exacerbations has not been established. The main benefit of structured telephone support or non-invasive telemonitoring may be to improve titration of and adherence to pharmacological therapy and to reinforce advice about lifestyle. This may account for why a 24/7 does not appear superior to an office-hours service. Lack of patientengagement and patient-preference may account for the failure of some methodologies such as voice-interactive systems.
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